Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,050,311
  • Shares Outstanding, K 140,011
  • Annual Sales, $ 829,450 K
  • Annual Income, $ -1,630 K
  • EBIT $ 98 M
  • EBITDA $ 116 M
  • 60-Month Beta 1.21
  • Price/Sales 11.49
  • Price/Cash Flow 570.02
  • Price/Book 18.69

Options Overview Details

View History
  • Implied Volatility 65.61% (-7.85%)
  • Historical Volatility 57.58%
  • IV Percentile 39%
  • IV Rank 26.20%
  • IV High 118.81% on 04/08/25
  • IV Low 46.72% on 07/07/25
  • Expected Move (DTE 14) 6.94 (10.76%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 1,469
  • Volume Avg (30-Day) 2,303
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 43,402
  • Open Int (30-Day) 44,221
  • Expected Range 57.58 to 71.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.93
  • Number of Estimates 6
  • High Estimate 0.43
  • Low Estimate -1.46
  • Prior Year 2.75
  • Growth Rate Est. (year over year) -133.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.65 +4.66%
on 01/20/26
76.11 -15.23%
on 02/03/26
-6.29 (-8.88%)
since 01/06/26
3-Month
37.06 +74.10%
on 11/20/25
76.76 -15.95%
on 01/06/26
+24.92 (+62.93%)
since 11/06/25
52-Week
9.57 +574.19%
on 04/07/25
76.76 -15.95%
on 01/06/26
+44.04 (+215.04%)
since 02/06/25

Most Recent Stories

More News
Arrowhead Research: Fiscal Q1 Earnings Snapshot

Arrowhead Research: Fiscal Q1 Earnings Snapshot

ARWR : 64.52 (-0.19%)
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

- Conference Call and Webcast Today, February 5, 2026, at 4:30 p.m. ET

ARWR : 64.52 (-0.19%)
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

NEW YORK , Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: 

CIEN : 271.32 (+7.25%)
ADT : 8.07 (+2.80%)
ARWR : 64.52 (-0.19%)
OSW : 21.27 (+3.00%)
DVAX : 15.50 (+0.06%)
SPGI : 439.28 (-2.75%)
DAY : 69.86 (+1.36%)
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

- ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with a single RNAi molecule - In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and...

ARWR : 64.52 (-0.19%)
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026...

ARWR : 64.52 (-0.19%)
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the...

ARWR : 64.52 (-0.19%)
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

- REDEMPLO is being launched in China by Sanofi - NMPA approval triggers $10 million milestone payment to be paid by Sanofi to Arrowhead subsidiary Visirna Therapeutics

ARWR : 64.52 (-0.19%)
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032...

ARWR : 64.52 (-0.19%)
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

- ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on tirzepatide...

ARWR : 64.52 (-0.19%)
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLOâ„¢ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

– REDEMPLO is the first and only Health Canada-approved siRNA medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS – People living with FCS have extremely...

ARWR : 64.52 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

3rd Resistance Point 72.47
2nd Resistance Point 70.45
1st Resistance Point 67.49
Last Price 64.52
1st Support Level 62.51
2nd Support Level 60.49
3rd Support Level 57.53

See More

52-Week High 76.76
Last Price 64.52
Fibonacci 61.8% 51.09
Fibonacci 50% 43.17
Fibonacci 38.2% 35.24
52-Week Low 9.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar